Table 3 Patient and tumour characteristics
From: IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center
Variable | No. of patients | % | |
|---|---|---|---|
Total No. of patients | 39 | 100 | |
Age, years | |||
Median | 59 | ||
Range | 38-85 | ||
Sex | |||
Male | 8 | 21 | |
Female | 31 | 79 | |
HIV status | |||
positive | 3 | 8 | |
negative | 36 | 92 | |
T stage | |||
Tx | 1 | 3 | |
T1 | 2 | 5 | |
T2 | 11 | 28 | |
T3 | 18 | 46 | |
T4 | 7 | 18 | |
N stage | |||
N0 | 13 | 46 | |
N1 | 16 | 32 | |
N2 | 10 | 22 | |
N3 | 0 | 0 | |
M stage | |||
M0 | 37 | 95 | |
M1 | 2 | 5 | |
Stage | |||
I | 2 | 5 | |
II | 7 | 20 | |
IIIA | 27 | 70 | |
IV | 2 | 5 | |
Chemotherapy | |||
No. | 33 | 85 | |
FU/MMC | 19 | 46 | |
FU/cisplatin | 11 | 26 | |
RT dose, Gy | |||
PTV1 median | 45 | ||
range | 40-45 | ||
PTV2 median | 63 | ||
range | 40-65 | ||
RT break ≥ 3 days | |||
no | 31 | 80 | |
yes | 8 | 20 | |
RT duration (d) | |||
median | 50 | ||
range | (21-69) |